Skip to main content
OpenTrials
Completed

NCT Number: NCT02690961

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gender: male or female, each sex ratio does not exceed 2/3;
  • 18-45 years (including upper and lower limit), the general situation is good;
  • Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight（BW）≥ 50kg (female) and 60kg (male);
  • Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
  • Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.

Exclusion criteria

  • Primary disease in important organs;
  • Mental or physical disability;
  • Familial hereditary disease;
  • Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
  • Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
  • History of immunodeficiency diseases, including HIV antibody positive;
  • Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;
  • Alcohol and drug abusers;
  • Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;
  • Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;
  • Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, etc.), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form（CRF）;
  • The last 3 months had a history of blood donation or significant blood loss (more than 400ml);
  • There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;
  • Lactating women, pregnant women or unable to take effective contraceptive measures;
  • Researchers believe that participants not suitable to take the test for other factors .

Treatment and study plan

Kukoamine B Mesilate

Drug

Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Placebo multiple doses

Drug

Primary outcomes

  1. Incidence of adverse events.

    Time frame: 14 days

    adverse event, physical examination, monitoring of vital signs, Laboratory examination, electrocardiogram(ECG).

Secondary outcomes

  1. Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])

    Time frame: the first day,the sixth day(before the three injections from bottom),the seventh day

    before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.

Other outcomes

  1. Pharmacokinetic parameters(Area Under Curve [AUC])

    Time frame: the first day,the sixth day(before the three injections from bottom),the seventh day

    before the first injecting(omin); after starting the first injecting 30min;ending the first injecting instantly,1h,3h,6h,8h,12h,16h,23h;before the three injections from bottom,after starting the last injecting 30min,ending the last injecting instantly,1h,3h,6h,8h,12h,16h,23h.

Sponsors and collaborators

Lead sponsor

Tianjin Chasesun Pharmaceutical Co., LTD

Industry

Collaborators

  • Southwest Hospital, China

Registry information

Official study title

Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Feb 24, 2016
Registry last updated
May 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.